JACQUES JM
VAN DONGEN
Investigador
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Pfizer (United States) (3)
2005
-
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
Cancer, Vol. 104, Núm. 7, pp. 1442-1452
2002
-
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
Leukemia, Vol. 16, Núm. 9, pp. 1627-1636
1990
-
Trimetrexate efficacy and pharmacokinetics during treatment of refractory pneumocystis carinii pneumonia in an infant with severe combined immunodeficiency disease
Pediatric Infectious Disease Journal, Vol. 9, Núm. 3, pp. 212-214